In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

CRISPR Therapeutics AG

www.crisprtx.com

Latest From CRISPR Therapeutics AG

Deal Watch: Boehringer, Epizyme Team Up To Develop Epigenetic Cancer Therapies

BI and Epizyme’s collaboration will focus on developing novel cancer drugs targeting helicase and HAT enzyme dysregulation. MorphoSys and I-Mab will partner on developing an IO therapy targeting C5aR.

Deals Business Strategies

Editas' EDIT-101 Set To Be First In Vivo CRISPR Gene-Editing Therapy In Clinic

Editas CEO says recent IND filing to treat LCA10 eye disease puts EDIT-101 on track to be first CRISPR medicine administered directly to patients. Bosley also voices relief at recent US IP court ruling.

Business Strategies Clinical Trials

Early-Stage Cell And Gene Therapy Progress: Updates From Casebia, BlueRock, Athersys, Cynata

Scrip caught up with several companies during the recent Cell and Gene Meeting on the Mesa, sponsored by the Alliance for Regenerative Medicine.

Regenerative Medicine Business Strategies

Partnering In Cell And Gene Therapy Is A Unique Endeavor

Industry and academic representatives shared viewpoints at Biotech Week Boston in September 2018, including what is unique about deal-making in the cell and gene field.

Regenerative Medicine Deals
See All

Company Information

  • Industry
  • Biotechnology
    • Drug Discovery Tools
      • Genomics-Proteomics
    • Gene Therapy, Cell Therapy
    • Large Molecule
  • Pharmaceuticals
  • Therapeutic Areas
  • Blood & Coagulation Disorders & Products
  • Hepatic (Liver)
  • Immune Disorders
  • Metabolic Disorders
  • Musculoskeletal & Connective Tissue Disorders
  • Respiratory, Pulmonary
  • Alias(es)
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • Switzerland
  • Company Type
  • Start-Up
  • Parent & Subsidiaries
  • CRISPR Therapeutics AG
  • Senior Management
  • Samarth Kulkarni, PhD, CEO
    Michael Tomsicek, CFO
    Rodger Novak, PhD, Pres.
    Lawrence Klein, PhD, Head, Bus. Dev. & Strategy
    Tony Ho, MD, Head, R&D
  • Contact Info
  • CRISPR Therapeutics AG
    Phone: 41 561 32 77
    Baarerstrasse 14
    Zug, V8 CH-6300
    Switzerland
Advertisement
Advertisement
UsernamePublicRestriction

Register